Beyond LDL: The Hidden Lipid Risks Still Driving Heart Disease
Even with optimal LDL control, remnant cholesterol, Lp(a), and apoB drive ongoing ASCVD risk — and new therapies are emerging to address them.
Summary
Most people and clinicians focus on LDL cholesterol as the primary lipid target for heart disease prevention, but a major review in the European Heart Journal reveals that significant cardiovascular risk persists even when LDL is well-controlled. Three independent lipid fractions — remnant cholesterol, lipoprotein(a), and LDL — each drive atherosclerosis through distinct mechanisms. Remnant particles deposit cholesterol in artery walls and may trigger inflammation leading to plaque rupture. Lp(a) promotes both plaque buildup and blood clotting. The review provides clinicians with updated guidance on measuring and targeting these often-overlooked fractions, and surveys a new generation of therapies designed to reduce residual cardiovascular risk beyond standard statin treatment.
Detailed Summary
Heart disease remains the world's leading killer, and for decades lowering LDL cholesterol has been the central strategy. Yet a large proportion of patients on optimal LDL-lowering therapy — including high-intensity statins and PCSK9 inhibitors — still experience heart attacks and strokes. This 'residual lipid risk' is now a major focus of cardiovascular research and clinical practice.
This comprehensive review, published in the European Heart Journal by leading lipidologists Nordestgaard and Hegele, examines which non-LDL lipid fractions are responsible for this persistent risk and what can be done about them. The authors identify remnant cholesterol, lipoprotein(a) [Lp(a)], and LDL as three independent causal drivers of atherosclerotic cardiovascular disease (ASCVD), each operating through distinct biological pathways.
Remnant cholesterol — derived from triglyceride-rich lipoproteins — contributes to arterial wall cholesterol accumulation much like LDL, but its additional triglyceride content may uniquely promote intimal inflammation and increase risk of plaque rupture and erosion. Lp(a) acts on two fronts: its lipid cargo fuels plaque development while its structural similarity to plasminogen may impair fibrinolysis and promote thrombosis, potentially worsening cardiovascular outcomes independently of atherogenesis. Composite markers like apolipoprotein B (apoB) and non-HDL cholesterol capture all three fractions, but interpreting them is clinically nuanced since the underlying drivers vary by patient.
The review synthesizes recent advances in therapies targeting these non-LDL pathways, including RNA-based medicines for Lp(a) and novel triglyceride-lowering agents, offering practical guidance for clinicians on how to identify and treat residual lipid risk today.
Caveats include the review format, which synthesizes existing evidence rather than generating new data. Access to full-text details on specific trials and recommendations was unavailable, limiting granular assessment of the evidence grading provided.
Key Findings
- Remnant cholesterol, Lp(a), and LDL are three independent causal drivers of ASCVD with distinct mechanisms.
- Elevated remnant cholesterol promotes arterial inflammation and plaque rupture beyond simple cholesterol deposition.
- Lp(a) may worsen cardiovascular outcomes via both plaque formation and anti-fibrinolytic, pro-thrombotic effects.
- ApoB and non-HDL cholesterol are useful composite markers but mask clinically distinct underlying lipid drivers.
- New RNA-based and other targeted therapies are emerging to address residual lipid risk beyond LDL reduction.
Methodology
This is a narrative review article published in the European Heart Journal, authored by two senior lipidology researchers. It synthesizes existing evidence on the pathophysiology and clinical management of residual lipid risk in ASCVD. No original data collection or meta-analytic methods are described in the abstract.
Study Limitations
This summary is based on the abstract only, as the full text is not open access; specific evidence grades, trial citations, and therapeutic recommendations could not be reviewed. As a narrative review, the article may reflect author perspectives and is subject to selection bias in the literature surveyed. No new clinical data are generated by this publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.